Core Insights - HOPE Therapeutics has initiated patient care for treatment-resistant depression using the Ampa One Day (ONE-D) protocol, marking a significant advancement in TMS therapy [1][2] - The Ampa device has shown promising results with an 87% response rate and a 72% remission rate in nonrandomized trials when combined with D-cycloserine and lisdexamfetamine [1][5] - The ONE-D protocol reduces the treatment duration from 90 days to a single day, offering a new paradigm for patients suffering from severe depression [2][3] Company Overview - HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, is focused on building a network of interventional psychiatry clinics that provide various therapies, including TMS and neuroplastic medications [4] - The company is expanding its presence in Florida, with plans to operate six clinic locations by the end of 2025 [2][5] - Dr. Rebecca Cohen, the Medical Director of HOPE, is the first Ampa-certified psychiatrist in Florida, leading the deployment of the Ampa device [5] Treatment Protocol - The ONE-D protocol combines TMS with physician-prescribed D-cycloserine and lisdexamfetamine, aiming to achieve remission from treatment-resistant depression [4][5] - D-cycloserine has been shown to enhance the effectiveness of TMS significantly, with studies indicating a more than two-fold increase in treatment efficacy [1][3] Research and Development - NRx Pharmaceuticals is developing NRX-100 and NRX-101, targeting central nervous system disorders, including suicidal depression and PTSD [5][6] - NRX-101 has received Breakthrough Therapy designation for treating suicidal bipolar depression, highlighting the company's commitment to addressing critical mental health issues [6]

Core Insights - NRx Pharmaceuticals, Inc. is preparing to launch HOPE Therapeutics clinics in Fall 2025, focusing on treating suicidal depression, PTSD, traumatic brain injury, and cognitive dysfunction through a unique residential program that combines various therapies [1][6] - The company recently raised over $8.8 million from biotechnology investors to support its initiatives, with no variable rate features involved in the offering [3][6] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal depression and PTSD, utilizing its NMDA platform [5] - The company is advancing neuroplastic drug development, including NRX-100 (intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 receiving Fast Track Designation and NRX-101 receiving Breakthrough Therapy Designation for specific depression treatments [5][7] HOPE Therapeutics Initiative - HOPE Therapeutics will be the first program in the nation to integrate neuroplastic drugs with established treatments like transcranial magnetic stimulation and hyperbaric oxygen therapy, aiming for a response rate exceeding 90% [3][6] - The program will also include nutritional therapy and outdoor activities, creating a comprehensive treatment environment [1][3] Advisory Board and Leadership - Matthew Rockefeller has joined the advisory board of HOPE Therapeutics, enhancing the initiative's leadership and strategic direction [1][6] - The initiative is supported by prominent figures from leading family offices, emphasizing collaboration and innovation in addressing mental health challenges [2]

Core Insights - NRx Pharmaceuticals is set to launch HOPE Therapeutics clinics in Fall 2025, focusing on treating suicidal depression, PTSD, traumatic brain injury, and cognitive dysfunction through a unique one-week residential program that combines various therapies [1][5] - The program will be the first of its kind in the nation, integrating neuroplastic drugs like ketamine, transcranial magnetic stimulation, and hyperbaric oxygen therapy, along with nutritional therapy and supportive therapy [1][6] - The company recently raised over $8.8 million from biotechnology investors to support its initiatives, with no warrants or variable rate features involved [3][5] Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal depression and PTSD [4] - The company is advancing neuroplastic drug development, particularly NRX-100 (intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 receiving Fast Track Designation for treating suicidal ideation in depression [4] - HOPE Therapeutics, a subsidiary of NRx, aims to create a network of interventional psychiatry clinics offering innovative therapies for patients with suicidal depression and related disorders [6] Key Partnerships and Initiatives - Matthew Rockefeller has joined the advisory board of HOPE Therapeutics, enhancing the company's strategic direction [1][3] - The Global Passion Project, founded by Andrea Cartier Bartzen, emphasizes collaboration and innovation to address global challenges like suicidal depression and PTSD [2]